fiscal second quarter varian post strong revenu result
oncolog sale top consensu manag rais
revenu guidanc rang y/i growth prior start
includ impact currenc give guidanc dollar basi
think bit conserv given strong note oncolog
revenu growth far outpac oncolog gross order growth year
due fast eu convers sustain oper spend
expect increas compani take advantag opportun
expand salesforc strong revenu beat order
line tad light hard say way trade thursday
stock price-to-earnings multipl significantli comp maintain neutral
oncolog revenu strength may sustain
out-performance seem result unusu fast
turnaround book bill management note larg proport
unit ship quarter came order book prior
six month y/i sale growth updat total
revenu guidanc rang look easili achiev
may includ conservat macroeconom trend
potenti tariff likelihood acceler revenu
convers rate continu model y/i growth
up sg spend sg expens percentag revenu
higher expect quarter ad
salesforc softwar emerg market increas
halcyon trend remain healthi order slot
greenfield site come center emerg market
valuat rate neutral risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
varian report total revenu continu oper well
estim street note
street low quarter go report quarter lumpi
result beat oncolog proton revenu gross oncolog order
compani came forecast
varian post new probeam proton system order quarter
report proton revenu higher model
gross oncolog order y/i constant currenc includ y/i
america flat y/i constant currenc emea y/i constant
currenc apac region
gross margin bp better model driven gross
margin oncolog revenu sg spend percentag revenu
bp estim spend slightli lower
forecast thank larg revenu beat non-gaap cent
higher forecast
go street low quarter consensu
despit signific revenu beat quarter slightli reduc
oncolog revenu forecast back half oncolog revenu
growth outpac growth oncolog gross order percentag
actualsbtig estimate varianceoncolog revenu revenu revenu incom gross bp sg spend bp spend bp ebit bp tax bpssourc btig estim compani filingsvari
trail order convert revenu first half fiscal
year higher seen moder revenu convers
rate leav expect oncolog gross order
unchang proton revenu reduc forecast
acknowledg uncertainti time product segment
forecast revenu growth top end guidanc rang
 increas sg spend percentag revenu reflect
commentari invest hire around softwar offer
emerg market model non-gaap oper margin
low end guidanc rang also reduc project tax
rate slightli beyond chang model
forecast non-gaap ep midpoint
varian rate neutral feel current valuat ntm
ep estim fair expens varian premium multipl among
compani similar growth btig assign price target neutral-
rate stock risk includ halcyon adopt chang oper margin
capit spend slow hospit govern new
competit healthcar multipl gener trade lumpi quarterli
gross incom ebit btig estim compani filingsnewold changentm johnsonjnjsel bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap
varian incom oncolog total y/i good gross sg one-tim total oper incom loss invest incom pre-tax incom incom non- net incom continu net earn discontinu non- dilut share net ex select calendar loss net product product product oper ep ep btig estim compani report
varian revenu eoncolog gross america y/i net america order y/i gross emea y/i net emea order y/i gross apac order y/i net apac y/i gross y/i net order y/i trail month gross trail month net y/i contract y/i oncolog y/i gross y/i y/i y/i gross y/i y/i y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
